REPORT – This disease, which leads to vision loss, affects a quarter of those over 75 years of age. Every day at the Paris Hospital des Quinze-Vingts, 80 patients receive treatment directly injected into the eye to slow their progress.
A spring morning at the Quinze-Vingts National Hospital in Paris. The man who has been waiting for a few minutes in a small waiting room on the ground floor, in his sixties, seems stressed. Sitting in a seat, he twists his hands in all directions, looking anxiously at the door in front of him. This morning he must receive his very first injection against the age-related macular degeneration (DMLA) that attacks one of his eyes. The door abruptly opens on a nurse: “Come on, let’s go!».
Behind her, in what looks like a mini-operating room, a green-clad surgeon prepares a syringe. For long minutes, the doctor and nurse carefully disinfect the patient’s previously anesthetized eye, before gently pushing the needle – very thin – into it. «It’s always impressive the first time, many patients fear that their eyes will be punctured. But in reality it is harmless and completely painless